Background Ureteral stents are commonly used to ensure adequate drainage of the upper urinary tract in the presence, or anticipated occurrence, of ureteral obstruction. However, stent-related symptoms are frequent and represent a significant source of morbidity. Although several pharmacological treatment options are currently available, symptom relief remains often incomplete. In an effort to achieve better control of stent-related symptoms, we evaluated the efficacy of dose doubling in two commonly used drug combinations that have demonstrated symptomatic benefits in this context.
Hefnawy et al. (Tue,) studied this question.